데이터가 없습니다.

1. Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4?D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3?D3) in [ BREAST CANCER RESEARCH AND TREATMENT ] - 2023.09.01
2. Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/ non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis [ Esmo Open ] - 2023.06.01
3. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer [ SCIENTIFIC REPORTS ] - 2023.04.25
4. Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02 [ CLINICAL ONCOLOGY ] - 2023.02.01
5. Clinical outcomes of curative surgical resection of peritoneal metastasis in patients with colorectal cancer: A long-term follow-up study [ Cancer Medicine ] - 2023.02.01
6. Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice [ Cancer Control ] - 2022.12.01
7. Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study [ OncoImmunology ] - 2022.11.23
8. Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) [ BREAST ] - 2022.10.01
9. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer [ INTERNATIONAL JOURNAL OF CANCER ] - 2022.06.15
10. Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy [ Cancers ] - 2022.05.12
11. Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression [ CANCER RESEARCH AND TREATMENT ] - 2022.04.01
12. Real-world data analysis of patients with cancer of unknown primary [ SCIENTIFIC REPORTS ] - 2021.12.29
13. Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea-A Sarcoma-Specific, Institutional Registry-Based Analysis [ CANCER MANAGEMENT AND RESEARCH ] - 2021.11.24
14. A New Human Leukocyte Antigen Typing Algorithm Combined With Currently Available Genotyping Tools Based on Next-Generation Sequencing Data and Guidelines to Select the Most Likely Human Leukocyte Antigen Genotype [ FRONTIERS IN IMMUNOLOGY ] - 2021.10.01
15. Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice [ CLINICAL COLORECTAL CANCER ] - 2021.06.01
16. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [ SCIENTIFIC REPORTS ] - 2021.03.29
17. High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer [ EXPERIMENTAL AND MOLECULAR MEDICINE ] - 2021.03.22
18. The Role and Clinical Effectiveness of Multiline Chemotherapy in Advanced Desmoplastic Small Round Cell Tumor [ CLINICAL MEDICINE INSIGHTS-ONCOLOGY ] - 2021.02.17
19. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study [ EUROPEAN JOURNAL OF CANCER ] - 2021.02.01
20. Patterns of recurrence in patients with curative resected rectal cancer according to different chemoradiotherapy strategies: Does preoperative chemoradiotherapy lower the risk of peritoneal recurrence? [ Oncology Letters ] - 2020.11.01
21. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study [ TARGETED ONCOLOGY ] - 2020.08.15
22. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study [ TARGETED ONCOLOGY ] - 2019.12.01
23. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. [ EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ] - 2019.07.01
24. Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations [ BRITISH JOURNAL OF CANCER ] - 2019.04.01
25. Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. [ JOURNAL OF MOLECULAR DIAGNOSTICS ] - 2019.03.21
26. Prognostic Value of the Microsatellite Instability Status in Patients With Stage II/III Rectal Cancer Following Upfront Surgery [ Clinical Colorectal Cancer ] - 2018.12.17
27. Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience [ CHINESE JOURNAL OF CANCER RESEARCH ] - 2018.08.01
28. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment [ MEDICAL ONCOLOGY ] - 2018.04.05
29. Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS [ TRANSLATIONAL ONCOLOGY ] - 2018.04.01
30. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX) [ ANNALS OF SURGICAL ONCOLOGY ] - 2017.05.01

1. BRAF 돌연변이를 동반한 대장암에서 면역관문억제제와 BRAF 또는 MEK 억제제의 병합요법의 효용성 평가 - 2022.03.01 ~ 2023.02.28
2. BRAF 돌연변이를 동반한 대장암에서 면역관문억제제와 BRAF 또는 MEK 억제제의 병합요법의 효용성 평가 - 2021.09.01 ~ 2022.02.28
3. HER2 발현 진행성 고형 종양이 있는 시험대상자에서 SBT6050 단독요법 및 펨브롤리주맙과의 병용요법에 대한 공개 라벨, 용량 증량 및 확장 제 1 1b 상 임상시험 - 2021.03.03 ~ 2024.09.30
4. BRAF 돌연변이를 동반한 대장암에서 면역관문억제제와 BRAF 또는 MEK 억제제의 병합요법의 효용성 평가 - 2020.09.01 ~ 2021.08.31
5. 화학요법에 내성이 있고 절제불가능한 전이성 항문관 편평세포암종 환자를 대상으로 단독투여하거나 BI 836880과 병용투여하는 BI 754091을 평가하기 위한 공개라벨, 무작위배정, 제II상 임상시험 - 2020.06.15 ~ 2024.01.02
6. 육종암에서 NGS를 통한 neoantigen 발굴 및 neoantigen 특이적 T 림프구 규명 - 2020.01.01 ~ 2020.12.31
7. 복막전이 대장암에서 항암제 반응성과 관련된 유전자 발굴 및 검증 - 2020.01.01 ~ 2020.12.31
8. [KM10-A]2가지 요법 이상의 HER-2 표적 치료 후 진행된 HER-2 양성 전이성 유방암 환자에서 Trastuzumab biosimilar(Herzuma®)-Gedatolisib 병용요법의 안전성, 유효성 평가를 위한 다기관 제2상 임상시험 - 2019.12.10 ~ 2021.12.31
9. [KM10-B]2가지 요법 이상의 HER-2 표적 치료 후 진행된 HER2-양성 전이성 유방암 환자에서 Trastuzumab biosimilar (Herzuma®) 와 임상의가 선정한 약제와의 병용요법의 안전성, 유효성 평가를 위한 공개, 다기관, 전향적, 제 2상 임상시험 - 2019.12.10 ~ 2021.09.30
10. 상동재조합 돌연변이를 가진 고형암 환자에서 IDX-1197의 공개, 다기관, 제1b상／제2a상 바구니형 임상시험 - 2019.11.11 ~ 2023.10.31
11. 진행성 평활근육종 환자에서 이차치료요법으로서 아벨루맙과 젬시타빈 병용치료에 대한 제 2상 임상시험 - 2019.04.17 ~ 2020.12.31
12. 육종암에서 NGS를 통한 neoantigen 발굴 및 neoantigen 특이적 T 림프구 규명 - 2019.01.01 ~ 2019.12.31

데이터가 없습니다.

      데이터가 없습니다.

 공지